Latest Articles

Publication Date
Inguinal endometriosis: a rare entity of a common condition .

A woman in her mid-40s experienced a painful lump in the right groin area for 5 years, with exacerbation during menstruation, coughing and sneezing. Initial treatment with depot methylprednisolone acetate …

Published: Sept. 11, 2025, midnight
Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial - Reproductive Health

Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial Reproductive Health

Published: March 9, 2025, 9:57 p.m.
Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial.

Published: March 9, 2025, midnight
Primary Low-Grade Endometrial Stromal Sarcoma of the Ovary Arising From Endometriosis: A Case Report.

Low-grade endometrial stromal sarcoma (LGESS) is a rare mesenchymal tumor of female genital tract malignancies. While it primarily arises in the uterus, extrauterine cases, including those originating in the ovary, …

Published: Feb. 23, 2025, midnight
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
SAHPRA Issues Warning on Meningioma Risk with Medroxyprogesterone Acetate Use, Updates Product Information - Devdiscourse

SAHPRA Issues Warning on Meningioma Risk with Medroxyprogesterone Acetate Use, Updates Product Information Devdiscourse

Published: Jan. 17, 2025, 4:01 p.m.
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …

Published: Jan. 8, 2025, midnight
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA …

Published: Dec. 11, 2024, midnight
Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.

To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related …

Published: Dec. 9, 2024, midnight
Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT.

Endometriosis affects 1 in 10 women, many of whom have surgery for persistent pain. Recurrence of symptoms following an operation is common. Although hormonal treatment can reduce this risk, there …

Published: Oct. 13, 2024, 8:56 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!